Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Towards personalized treatment of smoking-related lung cancers

Access options



  1. Jamal-Hanjani, M. et al. N. Engl. J. Med. 376, 2109–2121 (2017).

    PubMed  Article  Google Scholar 

  2. Blakely, C. M. et al. Nature Genet. 49, 1693–1704 (2017).

    PubMed  Article  Google Scholar 

  3. Castiglione, R. et al. Mod. Pathol. 32, 627–638 (2019).

    PubMed  Article  Google Scholar 

  4. McFadden, D. G. et al. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016).

    PubMed  Article  Google Scholar 

  5. Yuan, G. et al. Nature 590, 504–508 (2021).

    PubMed  Article  Google Scholar 

Download references

Competing Interests

G.M. reported receiving research funding from Bristol-Myers Squibb, Kael-Gemvax, Merck Sharp & Dome and Plexxikon, and personal fees from BioLineRx, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dome and Roche.


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links